Drug Profile
CCI 15106
Alternative Names: CCI15106Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Bronchodilators
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation, Powder)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation, Capsule)
- 19 Jun 2018 GlaxoSmithKline completes a phase I trial in Chronic obstructive pulmonary disease in United Kingdom (Inhalation, Powder) (NCT03235726)